berberine has been researched along with Hyperglycemia, Postprandial in 24 studies
Hyperglycemia, Postprandial: Abnormally high BLOOD GLUCOSE level after a meal.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Berberine and Bifidobacterium have been reported to improve glucose tolerance in people with hyperglycemia or other metabolic disorders." | 9.41 | Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. ( Ding, C; Du, Y; Fang, Y; Gao, X; He, Q; Ji, Q; Li, C; Li, S; Luo, S; Ma, K; Ming, J; Tian, Z; Wang, L; Wang, X; Wang, Z; Xie, X; Xu, X; Yang, W; Yu, X; Zhao, J, 2021) |
| "Dysregulated glucagon drives hyperfunction in hepatic glucose output, which is the main cause of persistent hyperglycemia in type 2 diabetes." | 7.96 | Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. ( Jiang, B; Jin, J; Liu, P; Sheng, L; Song, Y; Zhang, H; Zhong, Y; Zhou, H, 2020) |
| "This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 7.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
| " The aim of the present study was to examine the protective effect of the alkaloid drug berberine against hyperglycemia-induced cellular injury and endothelial dysfunction." | 7.75 | Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. ( Huang, Y; Lam, KS; Lau, CW; Li, Y; Vanhoutte, PM; Wang, Y; Wong, WT; Xu, A; Ye, H, 2009) |
| "Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved." | 5.51 | Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. ( Dang, Y; Ji, G; Li, M; Li, Q; Yao, Z; Zhang, L; Zhou, W; Zuo, J, 2019) |
| "Berberine and Bifidobacterium have been reported to improve glucose tolerance in people with hyperglycemia or other metabolic disorders." | 5.41 | Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. ( Ding, C; Du, Y; Fang, Y; Gao, X; He, Q; Ji, Q; Li, C; Li, S; Luo, S; Ma, K; Ming, J; Tian, Z; Wang, L; Wang, X; Wang, Z; Xie, X; Xu, X; Yang, W; Yu, X; Zhao, J, 2021) |
| "Dysregulated glucagon drives hyperfunction in hepatic glucose output, which is the main cause of persistent hyperglycemia in type 2 diabetes." | 3.96 | Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice. ( Jiang, B; Jin, J; Liu, P; Sheng, L; Song, Y; Zhang, H; Zhong, Y; Zhou, H, 2020) |
| "This study investigated the effects of berberine on amelioration of hyperglycemia and hyperlipidemia and the mechanism involved in high glucose and high fat diet-induced diabetic hamsters." | 3.81 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo. ( Jin, J; Li, L; Li, P; Liu, C; Song, Y; Wang, Z; Wu, D; Xu, N; Zheng, X, 2015) |
| "Berberine (BBR) has recently been shown to improve insulin sensitivity in rodent models of insulin resistance." | 3.78 | Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. ( Duarte, FV; Gomes, AP; Hubbard, BP; Jones, JG; Nunes, P; Palmeira, CM; Rolo, AP; Sinclair, DA; Teodoro, JS; Varela, AT, 2012) |
| " Berberine (BBR) has recently been shown to lower blood glucose levels and to improve insulin resistance in db/db mice partly through the activation of AMP-activated protein kinase (AMPK) signaling and induction of phosphorylation of insulin receptor (IR)." | 3.76 | Berberine inhibits PTP1B activity and mimics insulin action. ( Chen, C; Huang, C; Zhang, Y, 2010) |
| " The aim of the present study was to examine the protective effect of the alkaloid drug berberine against hyperglycemia-induced cellular injury and endothelial dysfunction." | 3.75 | Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. ( Huang, Y; Lam, KS; Lau, CW; Li, Y; Vanhoutte, PM; Wang, Y; Wong, WT; Xu, A; Ye, H, 2009) |
| "A berberine pretreatment attenuated paliperidone-induced increases in blood concentrations of glucose, adrenaline, and insulin and phosphorylated AMPK concentrations in the hypothalamus." | 1.72 | Paliperidone-Induced Acute Hyperglycemia Is Caused by Adrenaline Secretion via the Activation of Hypothalamic AMP-Activated Protein Kinase. ( Aoyama, T; Ishiwata, Y; Kawano, Y; Nagata, M; Negishi, K; Takahashi, H; Xue, B, 2022) |
| "Postprandial hyperglycemia is an important causative factor of type 2 diabetes mellitus, and permanent localization of intestinal GLUT2 in the brush border membrane is an important reason of postprandial hyperglycemia." | 1.62 | Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice. ( Dong, L; Li, J; Yang, E; Yang, H; Zhang, M, 2021) |
| "Berberine (BBR) is a widely used anti-diabetic agent, and liver glucokinase (GK) has been reported to be involved." | 1.51 | Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice. ( Dang, Y; Ji, G; Li, M; Li, Q; Yao, Z; Zhang, L; Zhou, W; Zuo, J, 2019) |
| " This work intended to develop selenium-coated nanostructured lipid carriers (SeNLCs) for enhancing the oral bioavailability and the curative effect of berberine, an antidiabetic phytomedicine." | 1.46 | Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect. ( Hou, Y; Song, X; Yin, J; Yin, Y, 2017) |
| "Berberine is an isoquinoline alkaloid widely used in Asian countries as a traditional medicine." | 1.38 | Possible therapeutic potential of berberine in diabetic osteopathy. ( Bhutada, PS; Kaulaskar, SV; Rahigude, AB, 2012) |
| "Berberine treatment reduced the plasma sugar and lipid levels by 24-69% in the rat model of hyperglycemia and hypercholesterolemia." | 1.37 | Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats. ( Dong, SF; Hao, YZ; Hong, Y; Liu, M; Liu, Y; Sun, JN; Yu, HS, 2011) |
| "Berberine was found to effectively inhibit the activity of disaccharidases in Caco-2 cells." | 1.32 | The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. ( Fawcett, JP; Huang, ZJ; Liu, XD; Pan, GY; Sun, JG; Wang, GJ; Xie, YY; Zhao, XC, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 9 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, MM | 1 |
| Lu, J | 1 |
| Li, S | 2 |
| Wang, H | 1 |
| Cao, X | 1 |
| Li, Q | 2 |
| Shi, TT | 1 |
| Matsunaga, K | 1 |
| Chen, C | 2 |
| Huang, H | 2 |
| Izumi, T | 1 |
| Yang, JK | 1 |
| Wang, N | 1 |
| Wang, L | 2 |
| Zhang, C | 1 |
| Tan, HY | 1 |
| Zhang, Y | 2 |
| Feng, Y | 1 |
| Zhang, M | 1 |
| Yang, H | 1 |
| Yang, E | 1 |
| Li, J | 1 |
| Dong, L | 1 |
| Xue, B | 1 |
| Ishiwata, Y | 1 |
| Kawano, Y | 1 |
| Takahashi, H | 1 |
| Negishi, K | 1 |
| Aoyama, T | 1 |
| Nagata, M | 1 |
| Purwaningsih, I | 1 |
| Maksum, IP | 1 |
| Sumiarsa, D | 1 |
| Sriwidodo, S | 1 |
| Zhong, Y | 1 |
| Jin, J | 2 |
| Liu, P | 2 |
| Song, Y | 2 |
| Zhang, H | 2 |
| Sheng, L | 1 |
| Zhou, H | 1 |
| Jiang, B | 1 |
| Li, M | 2 |
| Zhou, W | 2 |
| Dang, Y | 2 |
| Li, C | 2 |
| Ji, G | 2 |
| Zhang, L | 2 |
| Yin, Z | 1 |
| Tan, R | 1 |
| Yuan, T | 1 |
| Chen, S | 1 |
| Quan, Y | 1 |
| Hao, Q | 1 |
| Zeng, J | 1 |
| Zhao, J | 2 |
| Li, L | 2 |
| Ming, J | 1 |
| Yu, X | 1 |
| Xu, X | 1 |
| Ding, C | 1 |
| Wang, Z | 2 |
| Xie, X | 2 |
| Yang, W | 1 |
| Luo, S | 1 |
| He, Q | 1 |
| Du, Y | 1 |
| Tian, Z | 1 |
| Gao, X | 1 |
| Ma, K | 1 |
| Fang, Y | 1 |
| Wang, X | 1 |
| Ji, Q | 1 |
| Yin, J | 1 |
| Hou, Y | 1 |
| Yin, Y | 1 |
| Song, X | 1 |
| Yue, X | 1 |
| Liang, J | 1 |
| Gu, F | 1 |
| Du, D | 1 |
| Chen, F | 1 |
| Zuo, J | 1 |
| Yao, Z | 1 |
| Liu, C | 1 |
| Wu, D | 2 |
| Zheng, X | 1 |
| Li, P | 1 |
| Xu, N | 1 |
| Ma, YG | 1 |
| Zhang, YB | 1 |
| Bai, YG | 1 |
| Dai, ZJ | 1 |
| Liang, L | 1 |
| Liu, M | 2 |
| Xie, MJ | 1 |
| Guan, HT | 1 |
| Yang, N | 1 |
| Sun, RB | 1 |
| Chen, XL | 1 |
| Zhen, L | 1 |
| Ge, C | 1 |
| Zhao, YQ | 1 |
| He, J | 1 |
| Geng, JL | 1 |
| Guo, JH | 1 |
| Yu, XY | 1 |
| Fei, F | 1 |
| Feng, SQ | 1 |
| Zhu, XX | 1 |
| Wang, HB | 1 |
| Fu, FH | 1 |
| Aa, JY | 1 |
| Wang, GJ | 2 |
| Wang, Y | 1 |
| Huang, Y | 1 |
| Lam, KS | 1 |
| Li, Y | 1 |
| Wong, WT | 1 |
| Ye, H | 1 |
| Lau, CW | 1 |
| Vanhoutte, PM | 1 |
| Xu, A | 1 |
| Wei, J | 1 |
| Xue, R | 1 |
| Wu, JD | 1 |
| Zhao, W | 1 |
| Wang, ZZ | 1 |
| Wang, SK | 1 |
| Zhou, ZX | 1 |
| Song, DQ | 1 |
| Wang, YM | 1 |
| Pan, HN | 1 |
| Kong, WJ | 1 |
| Jiang, JD | 1 |
| Huang, C | 1 |
| Dong, SF | 1 |
| Hong, Y | 1 |
| Hao, YZ | 1 |
| Yu, HS | 1 |
| Liu, Y | 1 |
| Sun, JN | 1 |
| Li, W | 1 |
| Lan, T | 1 |
| Liu, W | 1 |
| Peng, J | 1 |
| Huang, K | 1 |
| Huang, J | 1 |
| Shen, X | 1 |
| Gomes, AP | 1 |
| Duarte, FV | 1 |
| Nunes, P | 1 |
| Hubbard, BP | 1 |
| Teodoro, JS | 1 |
| Varela, AT | 1 |
| Jones, JG | 1 |
| Sinclair, DA | 1 |
| Palmeira, CM | 1 |
| Rolo, AP | 1 |
| Wen, W | 1 |
| Qi, CL | 1 |
| Zhao, RX | 1 |
| Lü, JH | 1 |
| Zhong, CY | 1 |
| Chen, YY | 1 |
| Rahigude, AB | 1 |
| Kaulaskar, SV | 1 |
| Bhutada, PS | 1 |
| Pan, GY | 1 |
| Huang, ZJ | 1 |
| Fawcett, JP | 1 |
| Liu, XD | 1 |
| Zhao, XC | 1 |
| Sun, JG | 1 |
| Xie, YY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Berberine on Insulin Release at a High Blood Glucose Level in Normal Man[NCT03972215] | Early Phase 1 | 15 participants (Actual) | Interventional | 2019-10-01 | Completed | ||
| Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.[NCT03330184] | 300 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for berberine and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
A Review of
Topics: Alkaloids; Antioxidants; Berberine; Humans; Hyperglycemia; Hypoglycemic Agents; Menispermaceae | 2023 |
3 trials available for berberine and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.
Topics: Adolescent; Adult; Animals; Berberine; Cell Line, Tumor; Cross-Over Studies; Diet, High-Fat; Ether-A | 2021 |
Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study.
Topics: Aged; Berberine; Bifidobacterium; Blood Glucose; Combined Modality Therapy; Disease Management; Fece | 2021 |
Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
Topics: Aged; Berberine; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Female; Gene Expression; Human | 2010 |
20 other studies available for berberine and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Berberine suppresses advanced glycation end products-associated diabetic retinopathy in hyperglycemic mice.
Topics: Animals; Berberine; Diabetic Retinopathy; Disease Models, Animal; Glycation End Products, Advanced; | 2021 |
Berberine Decreases Intestinal GLUT2 Translocation and Reduces Intestinal Glucose Absorption in Mice.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cell Line; Diabetes Mellitus, Experimental; Epitheli | 2021 |
Paliperidone-Induced Acute Hyperglycemia Is Caused by Adrenaline Secretion via the Activation of Hypothalamic AMP-Activated Protein Kinase.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Glucose; Hyperglycemia; Hypothalamus; Insulin; Pa | 2022 |
Berberine Attenuates Hyperglycemia by Inhibiting the Hepatic Glucagon Pathway in Diabetic Mice.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Glucagon; Hyperglycemia; Liver; Mice; Mice, Obe | 2020 |
Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice.
Topics: Animals; Berberine; Colon; Gastrointestinal Microbiome; Glucagon-Like Peptides; Hyperglycemia; Male; | 2020 |
Berberine prevents diabetic retinopathy through inhibiting HIF-1α /VEGF/ NF-κ B pathway in db/db mice.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Hyperglyce | 2021 |
Selenium-coated nanostructured lipid carriers used for oral delivery of berberine to accomplish a synergic hypoglycemic effect.
Topics: Administration, Oral; Animals; Berberine; Biological Availability; Caco-2 Cells; Delayed-Action Prep | 2017 |
Berberine activates bitter taste responses of enteroendocrine STC-1 cells.
Topics: Berberine; Cell Line, Tumor; Enteroendocrine Cells; Estrenes; Glucagon-Like Peptide 1; Humans; Hyper | 2018 |
Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice.
Topics: Animals; Berberine; Blood Glucose; Diabetes Mellitus, Type 2; Glucokinase; Glucose; Hepatocytes; Hum | 2019 |
Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo.
Topics: Animals; Berberine; Blood Glucose; Cardiovascular Diseases; Cricetinae; Diabetes Mellitus, Experimen | 2015 |
Berberine alleviates the cerebrovascular contractility in streptozotocin-induced diabetic rats through modulation of intracellular Ca²⁺ handling in smooth muscle cells.
Topics: Animals; Berberine; Blood Glucose; Calcium; Calcium Channels, L-Type; Diabetes Mellitus, Experimenta | 2016 |
In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine.
Topics: Animals; Berberine; Glucuronides; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Mice, Inbred C57 | 2017 |
Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Apoptosis; Berberine; Cell Adhesion; Cell Line; Endot | 2009 |
Berberine inhibits PTP1B activity and mimics insulin action.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Berberine; Diet; Female; Hyperglycemia; Hypoglycemic Agents; Insu | 2010 |
Berberine attenuates cardiac dysfunction in hyperglycemic and hypercholesterolemic rats.
Topics: Animals; Berberine; Biomarkers; Dietary Fats; Gene Expression Regulation; Glucose Transporter Type 4 | 2011 |
Berberine ameliorates hyperglycemia in alloxan-induced diabetic C57BL/6 mice through activation of Akt signaling pathway.
Topics: Animals; Berberine; Blood Glucose; Blotting, Western; Diabetes Mellitus, Experimental; Glucokinase; | 2011 |
Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Cell Line; Diet, High-Fat; Glucose; Hormones; Hyp | 2012 |
Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin.
Topics: Animals; Berberine; Blood Glucose; Body Weight; Cholesterol; Creatinine; Diabetes Mellitus, Experime | 2012 |
Possible therapeutic potential of berberine in diabetic osteopathy.
Topics: Berberine; Calcitonin; Diabetes Complications; Glucagon-Like Peptides; Glycation End Products, Advan | 2012 |
The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption.
Topics: alpha-Glucosidases; Berberine; Caco-2 Cells; Enzyme Activation; Enzyme Inhibitors; Gluconeogenesis; | 2003 |